Silexion Therapeutics (SLXN) selected a contract research organization to support its upcoming Phase 2/3 clinical trials for SIL204, the Company’s next-generation siRNA candidate targeting KRAS-driven solid tumor cancers. The selected CRO, AMS Advanced Medical Services, brings extensive expertise in oncology clinical development and regulatory affairs, with over 28 years of experience and a proven track record in managing complex international clinical trials. The partnership is expected to support Silexion’s planned regulatory submissions to the Israel Ministry of Health in the fourth quarter of 2025 and to the European Union in the first quarter of 2026, with Phase 2/3 clinical trials expected to commence in the first half of 2026. Silexion expects to finalize the partnership agreement with AMS shortly following this selection. The collaboration is expected to encompass regulatory strategy, clinical trial design, site selection and management, and data analysis for the Company’s planned Phase 2/3 study evaluating SIL204’s dual-route administration approach in patients with locally advanced pancreatic cancer.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLXN:
- Silexion Therapeutics Unveils New Oncogene Therapy Updates
- Silexion Therapeutics Executes Reverse Stock Split
- Silexion Therapeutics Increases Authorized Share Capital
- Silexion Therapeutics reports Q2 EPS ($4.32) vs. ($197.80) last year
- Buy Rating for Silexion Therapeutics Driven by Promising Preclinical Data and Financial Strength